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B cells perform many immunological functions,
including presenting lipid antigen to CD1d-re-
stricted invariant natural killer T (iNKT) cells, known
to contribute to maintaining tolerance in autoimmu-
nity. Patients with systemic lupus erythematous
(SLE) display dysregulated B cell responses and
reduced peripheral iNKT cell frequencies. The sig-
nificance of these defects and how they relate to
SLE pathogenesis remain elusive. We report that
B cells are essential for iNKT cell expansion and
activation in healthy donors but fail to exert a simi-
lar effect in SLE patients. Defective B cell-mediated
stimulation of iNKT cells in SLE patients was associ-
ated with altered CD1d recycling, a defect reca-
pitulated in B cells from healthy donors after
stimulation with interferon-a (IFN-a) and anti-immu-
noglobulin (Ig). iNKT cell number and function were
restored in SLE patients responding to anti-CD20
treatment upon normalization of CD1d expression
exclusively in repopulated immature B cells. We
propose that healthy B cells are pivotal for iNKT
cell homeostasis.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex autoimmune
disease with an unclear etiology (Rahman and Isenberg, 2008).
Aberrant B cell responses and the production of autoantibodies
are considered hallmarks of the disease (Lipsky, 2001). The
important role of B cells in SLE pathogenesis is further proven
by the clinical success of B cell depletion therapy (CD20 mAb;
rituximab) (Leandro et al., 2005). As well as producing anti-
bodies, B cells release cytokines and chemokines and present
both peptide and lipid antigen (Batista and Harwood, 2009;
Lund and Randall, 2010). Although the majority of studies
have focused on the effect that peptide-antigen presentation
has on CD4+ T cell differentiation, there is little information
regarding the effect that B cells, presenting lipid antigen viaCD1d, have on invariant natural killer T (iNKT) cell activation
and differentiation.
iNKT cells perform critical functions in a broad range of
immune responses including protection from specific pathogens
and tumors, promotion of airway hyperreactivity, and themainte-
nance of tolerance in autoimmunity (Berzins et al., 2011; Wilson
and Delovitch, 2003). Changes in iNKT cell frequency have
been reported in patients with autoimmune disease. However,
the cause of this reduction remains to be ascertained (Kukreja
et al., 2002; Tudhope et al., 2010). Activation of iNKT cells
occurs via presentation of exogenous or endogenous lipid
antigen by CD1d expressed on a variety of antigen-presenting
cells (APCs). Although the nature of the natural activating
ligand(s) remains controversial, a marine-sponge-derived glyco-
lipid, a-galactosylceramide (aGalCer), potently activates iNKT
cells (Kawano et al., 1997). Engagement of the invariant T cell
receptor (iTCR) by CD1d-lipid complexes leads to rapid iNKT
cell activation, the prompt production of T helper 1 (Th1) cell
and Th2-like cytokines, and the upregulation of several costimu-
latory molecules (Cerundolo et al., 2009). These events
contribute to the reciprocal activation of APCs, for example,
the release of interleukin-12 (IL-12) by dendritic cells (DCs) and
the promotion of B cell maturation into plasma cells (Barral
et al., 2008; Lang et al., 2008). Conversely, marginal zone (MZ)
B cells activate iNKT cells via DCs (Bialecki et al., 2009), support-
ing an indirect function for B cells in iNKT cell homeostasis.
Overall, the effect that B cell lipid-antigen presentation has on
CD1d-restricted iNKT cell function in humans remains unclear.
We examined whether B cells are required for the in vitro and
in vivo maintenance of iNKT cells from healthy donors and SLE
patients. We demonstrated that B cells sustained iNKT cell
homeostasis and activation in healthy donors but not in SLE
patients. Patients were characterized by a decrease in CD1d
cell surface expression exclusively on B cells and not on other
lipid-antigen-presenting cells, a phenomenon that could be
mimicked in vitro by simultaneous stimulation with interferon-a
(IFN-a) and B cell receptor (BCR) engagement, factors associ-
ated with SLE pathogenesis (Bennett et al., 2003; Lipsky,
2001). We have shown that SLE patients responding to B cell
depletion therapy present normalized CD1d expression preva-
lently on repopulated CD19+CD24hiCD38hi immature B cells
and this positively correlated with the restoration of iNKT cell
number and function.Immunity 36, 477–490, March 23, 2012 ª2012 Elsevier Inc. 477
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B Cells Promote iNKT Cell Proliferation and Activation
in Healthy Donors
Previous work shows that peripheral blood mononuclear cell
(PBMC) stimulation with aGalCer and IL-2 leads to an exponen-
tial expansion of iNKT cells after 7–14 days (Watarai et al., 2008).
To determine the role of B cells presenting lipid antigen in this
process, we depleted B cells from PBMCs before stimulation
with aGalCer and IL-2. Removal of B cells from PBMCs impeded
the capacity of iNKT cells to expand in response to aGalCer and
IL-2 compared to undepleted PBMCs. Depletion of CD14+
monocytes, CD19CD1d+, CD19CD1c+ DCs, or CD19CD1c+
DCs together with CD14+monocytes did not significantly reduce
the capacity of iNKT cells to expand in response to aGalCer and
IL-2 (Figure 1A, Figure S1A available online, and data not shown
for CD19CD1c+ DCs or CD19CD1c+ DCs with CD14+ mono-
cytes). Removal of B cells led to a reduction in expression of
CD25 and Ki67, markers associated with activation and pro-
liferation, thus supporting the importance of B cells in the main-
tenance of iNKT cell homeostasis (Figure 1B). No difference
was observed in the expression of CD69 (data not shown).
We then proceeded to investigate the effect that removal of B
cells from PBMCs had on cytokine production driven by iNKT
cells upon stimulation with aGalCer and IL-2. In vitro depletion
of B cells led to a reduction of IFN-g, tumor necrosis factor-a
(TNF-a), IL-2, and IL-10 production at both day 4 and 7 after
stimulation (Figure 1C and data not shown for IL-2). No differ-
ence in IL-4 and IL-6 production were detected between B
cell-depleted and undepleted cultures (data not shown). Intra-
cellular detection of cytokines specifically produced by iNKT
cells further supported these data (Figure S1B).
To determine whether B cells directly, or indirectly via other
APCs, support iNKT cell proliferation, we cultured purified
iNKT cells with B cells preloaded with aGalCer in the presence
of IL-2. The results in Figure 1D display the fold increase in prolif-
eration, compared to unpulsed B cells and demonstrate that B
cells support iNKT cell expansion directly, as shown by the
fact that blockade of the CD1d-iTCR interaction inhibited iNKT
cell proliferation. Thus, B cells appear to be important for the
maintenance of iNKT cell number and function in healthy donors.
iNKT Cells in SLE Patients Are Numerically Decreased
and Functionally Impaired
Numerical defects in iNKT cell number have been previously re-
ported in patients with autoimmune disease including SLE (Tud-
hope et al., 2010; Wither et al., 2008). We demonstrated that
patients with SLE and other autoimmune diseases (OAD) in-
cluding Sjo¨gren’s syndrome and rheumatoid arthritis (RA) have
significantly reduced iNKT cell numbers in peripheral blood (PB)
(Figure 2A). The ratio of CD4+ and CD8+ iNKT cell subsets was
comparable in both healthy donors andpatients (data not shown).
To confirm that reduced iNKT cell number in SLEpatientswas not
due to iTCR internalization, we stained for both surface and intra-
cellular iTCR expression. The results in Figure 2B showed a lower
iNKT cell frequency in SLE patients compared to healthy donors.
Analysis of the ex vivo cytokine profile revealed a decrease in
IFN-g and an increase in IL-10-producing iNKT cell frequencies
in SLE patients compared to healthy donors. No differences478 Immunity 36, 477–490, March 23, 2012 ª2012 Elsevier Inc.were observed in the number of iNKT cells producing TNF-a (Fig-
ure 2C). Thus, iNKT cells from SLE patients display an altered
phenotype and cytokine milieu compared to healthy donors.
Abnormal B Cells from SLE Patients Induce Impaired
iNKT Cell Number and Function
Unlike those from healthy donors, iNKT cells from SLE patients
did not expand in vitro in response to aGalCer and IL-2 stimula-
tion (Figure 3A). Although iNKT cells failed to expand, analysis
of iNKT cells fromSLEpatients stainedwith 406diamidino-2-phe-
nylindole (DAPI) did not show increased mortality (data not
shown). The analysis of cytokines in the supernatants at day 7,
measured with a cytometric bead array (CBA), revealed that
iNKTcells fromSLEpatientswere incapable of driving the release
of IL-2, IFN-g, and TNF-a (Figure 3B). In contrast, production of
IL-10 driven by iNKT cells was increased in SLE patients
compared to healthy donors (Figure 3B), although production of
IL-4 and IL-6 remained unchanged (data not shown).
BecauseSLEpatientsarecharacterizedbysevereBcell abnor-
malities (Lipsky, 2001), we assessed their potential contribution
to driving iNKT cell dysfunction. B cells were depleted from
PBMCs fromhealthydonors and replacedwith negativelypurified
Bcells fromSLEpatients. Twocontrolswereused:purifiedBcells
fromhealthydonors culturedwith allogeneicPBMCs fromhealthy
donors depleted of B cells and purified B cells from SLE patients
cultured with allogeneic PBMCs from SLE patients depleted of B
cells (schematic representation of this experiment is depicted in
Figure 3C). In PBMC from healthy donors, replacement of B cells
with B cells from SLE patients reduced iNKT cell expansion and
their capacity toproduce IFN-gandTNF-a in response toaGalCer
and IL-2 stimulation compared to the response observed in
healthy allogeneic control (Figures 3D and 3E). Production of
IL-2 and IL-10 under these experimental conditions was below
the limit of detection (data not shown). Replacement of B cells
fromSLE patients with B cells from healthy donors did not rescue
the capacity of iNKT cells from SLE patients to proliferate in
response to lipid-antigen stimulation (Figure 3D) but did restore
their ability to produce IFN-g and TNF-a (Figure 3E). No restora-
tion effect was observed when allogeneic B cells from SLE
patients were cultured with PBMCs from SLE patients depleted
of B cells. Additionally, no detectable iNKT cell expansion or
cytokine production was seen when B cell-depleted PBMCs
from SLE patients were cultured alone (data not shown).
The results presented so far could be interpreted in two
different ways. One explanation is that B cells from SLE patients
are defective and fail to support iNKT cell proliferation and differ-
entiation. Alternatively, iNKT cells from SLE patients could be
intrinsically defective independent from the action of B cells.
However, the results displayed in Figures 3F and 3G show that
monocyte-derived dendritic cells (mDCs) isolated from SLE
patients were able to support both expansion and cytokine
release of iNKT cells from SLE patients, thus refuting the hypoth-
esis that iNKT cells from SLE patients are intrinsically defective.
B Cells from SLE Patients Present Defects in CD1d
Surface Expression and Intracellular Recycling
Compared to Healthy Donors
Our results indicated that B cell-mediated iNKT cell proliferation
was CD1d dependent (Figure 1D). This prompted us to examine
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Figure 1. B Cells Support iNKT Cell Expan-
sion and Activation in Healthy Donors
B cells or monocytes were depleted from PBMCs
obtained from healthy donors (n = 12). Depleted or
undepleted PBMCs were cultured with aGalCer
and IL-2 for 4 and 7 days. Supernatants were
collected for cytokine analysis and cells were
stained with CD3 and iTCR mAbs.
(A) Representative flow cytometry plots showing
frequency of iNKT cells at day 0, 4, and 7 in un-
depleted PBMCs from healthy donors and in B
cell- or monocyte-depleted PBMCs; bar chart
shows cumulative data as mean ± SE. *p < 0.05;
one-way ANOVA.
(B) Representative histograms showing CD25 and
Ki67 expression on iNKT cells from undepleted or
B cell-depleted PBMCs. Bar chart showing
mean ± SE. *p < 0.05, **p < 0.01; one-way ANOVA.
(C) Cytokines in supernatants collected from
experiment (A) were measured by cytometric bead
array (CBA). Bar charts show mean ± SE from 15
healthy donors. Data representative of four sepa-
rate experiments. *p < 0.05; paired t test.
(D) Negatively purified B cells pulsed with aGalCer
for 1 hr and cocultured 1:1 with positively purified
iNKT cells (105/well) with IL-2 ± isotype control or
blocking CD1d mAb for 48 hr. Proliferation was
determined by 3[H]TdR incorporation. Bar charts
show fold change ± SE in proliferation normalized
to unpulsed B cells in coculture with iNKT cells
with isotype control alone. Cumulative data
from three independent experiments with three
healthy donors each. Comparisons were between
aGalCer (aGC) pulsed and unpulsed cultures; *p <
0.01; one-way ANOVA.
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B Cells Sustain iNKT Cell Homeostasisthe expression of CD1d on B cells from healthy donors and SLE
patients with active disease. The expression of surface CD1d on
B cells from SLE patients was decreased compared to B cells
from healthy donors, whereas the expression of CD1d on mono-Immunity 36, 477–49cytes was equivalent in SLE patients and
healthy donors (Figure 4A). Given the pro-
found reduction in expression of CD1d on
B cells from SLE patients, we tested
whether increasing CD1d cell surface
expression on these cells could restore
their function. We used an established
method shown previously to force cyto-
toxic T lymphocyte antigen 4 to the
surface of regulatory T (Treg) cells
(Flores-Borja et al., 2008). Negatively iso-
lated B cells from healthy donors and SLE
patients were briefly stimulated with
phorbol myristate acetate (PMA), fixed,
and cultured with unmanipulated, autolo-
gous B cell-depleted PBMCs in the pres-
ence of aGalCer and IL-2 (Figure 4B). The
increment in CD1d expression on the
surface of B cells from SLE patients
restored their capacity to promote iNKT
cell proliferation and cytokine production
(Figures 4C and 4D), equivalent to therate observed after forcing CD1d to the surface of B cells from
healthy donors. Blocking CD1d expression with CD1d mAb,
specifically on B cells, prevented this increase. Similar results
were obtained when the internalization of CD1d was inhibited0, March 23, 2012 ª2012 Elsevier Inc. 479
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Figure 2. iNKT Cells in SLE Patients Are Numerically Decreased and Functionally Impaired
PBMCs from healthy donors or SLE patients were stained ex vivo for surface expression of CD3 and iTCR.
(A) Representative flow cytometry plots and cumulative data showing mean iNKT cell percentages and absolute numbers from 69 healthy donors, 254 SLE
patients, and 20 patients with other autoimmune disease (OAD). **p < 0.01, ****p < 0.0001; one-way ANOVA.
(B) PBMCs from healthy donors or SLE patients were stained for CD3 and iTCR extracellularly only (EC) or extra- and intracellularly (EC+IC). Representative flow
cytometry plots and cumulative data showing iNKT cell percentages from five healthy donors and four SLE patients.
(C) Representative flow cytometry plots displaying frequencies of IFN-g+, TNF-a+, and IL-10+ iNKT cells, mean ± SE. *p < 0.01; two-tailed t test.
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B Cells Sustain iNKT Cell Homeostasisin B cells with 0.4 M hypertonic sucrose, known to prevent cla-
thrin-mediated endocytosis (Idkowiak-Baldys et al., 2006),
hence retaining CD1d on the surface (data not shown).
CD1dmolecules are synthesized in the endoplasmic reticulum
and expressed on the cell surface before being reinternalized
and processed through the endosomal and lysosomal compart-
ments (De Silva et al., 2002; Jayawardena-Wolf et al., 2001).
Next, we examined whether abnormal CD1d recycling contrib-
uted to its reduced surface expression on B cells from SLE
patients. We have used PMA stimulation as a tool to study the
kinetics of CD1d internalization (Flores-Borja et al., 2008). The
results in Figure 4E revealed that B cells from SLE patients had
an increased rate of CD1d internalization, which peaked at
5 min, compared to B cells from healthy donors. In contrast,
CD1d internalization remained stable over time in B cells from
healthy donors. Further analysis by confocal microscopy re-
vealed that CD1d is localized at or near the plasma membrane,
immediately after PMA stimulation (0 min), in B cells from both
SLE patients and healthy donors (Figure 4F). CD1d on B cells
from SLE patients was aggregated compared to a more diffuse
distribution on B cells from healthy donors (Figure 4F). After al-
lowing endocytosis to proceed at 37C, CD1d on B cells from
healthy donors remained localized at or near the plasma
membrane after 5 min; however, in B cells from SLE patients,
CD1d appeared to migrate into the cell, confirming the results
obtained by flow cytometry (Figure 4F). Together, these results
suggest that increased CD1d internalization in B cells from
SLE patients could contribute to its reduced surface expression.
We next compared CD1d recycling dynamics in B cells from
SLE patients and healthy donors by using a method previously
established (Yuan et al., 2006). B cells were incubated at 4C
with saturating amounts of unconjugated CD1d mAb to block
cell surface CD1d molecules. We then incubated B cells at
37C for 20 min to allow intracellular CD1d molecules to recycle
to the cell surface. Because recycled intracellular CD1d mole-
cules were not protected by a prebound CD1d mAb, we could
assess their presence by staining with a CD1d-PE mAb and
flow cytometry. The results in Figure 4G showed that in B cells
from SLE patients, more CD1d was trafficked to the cell surface
compared to B cells from healthy donors. To ensure that only
preformed CD1d was measured during the time course of the
experiment, we inhibited synthesis of new CD1d with cyclohex-
amide (Chen et al., 2007).
We assessed whether decreased CD1d surface expression
reflected a reduction in the total cellular pool of CD1d. No differ-
ence in the total cellular expression of CD1d was observed in B
cells from SLE patients compared to B cells from healthy donors
by protein immunoblotting (Figure 4H). Furthermore, reduced
surface CD1d expression was not associated with increased
CD1d degradation as indicated by the fact that blocking
proteosomal (Figure 4I) and lysosomal function (with MG132
and chloroquine, respectively) (data not shown) did not reveal
any differences in total cellular CD1d expression between B cells
from healthy donors or from SLE patients. It has been shown
previously that surface CD1d molecules belong to a long-lived
pool, which continuously recycle between intracellular compart-
ments and the plasma membrane (Jayawardena-Wolf et al.,
2001). Therefore, our results suggest that reduced surface
expression of CD1d is not associated with an increased degra-dation of CD1d or with a reduction in total cellular CD1d but
rather with a potential defect in trafficking of CD1d in B cells
from SLE patients.
So far, our results suggest that inflammatory cues present in
SLE patients may be responsible for the reduced expression of
CD1d on B cells, which may affect iNKT cell homeostasis.
Increased BCR-related signaling and IFN-a production are hall-
marks of SLE pathogenesis (Bennett et al., 2003; Lipsky, 2001).
Following this line of reasoning, we stimulated B cells from
healthy donors with IFN-a alone or in combination with anti-
immunoglobulin (Ig) (to cross-link BCRs) and assessed the effect
on CD1d internalization. No effect on CD1d recycling was
observed when B cells from healthy donors were stimulated
with either IFN-a or anti-Ig alone. In contrast, simultaneous
stimulation with IFN-a and anti-Ig increased CD1d recycling on
B cells from healthy donors, to the rate observed in B cells
from SLE patients (Figure 4J). Additionally, IFN-a- and anti-Ig-
stimulated B cells had a reduced capacity to directly induce
iNKT cell proliferation and IFN-g production (Figures 4K and 4L).
iNKT Cell Number and Function Is Recovered in SLE
Patients Responding to Rituximab Treatment after B
Cell Repopulation
Our in vitro results showed that B cells and their expression of
CD1d are pivotal for the maintenance of iNKT cell number and
function. Therefore, we exploited the opportunity to investigate
the effect that in vivo B cell depletion has on iNKT cell homeo-
stasis in SLE patients undergoing B cell-depletion therapy. After
rituximab treatment, patients can either relapse or remain in full
or partial remission, concomitant with B cell repopulation (Lean-
dro et al., 2005; Ng et al., 2007). Patients were divided into four
groups: prior to rituximab treatment (SLE with active disease
assessed by British Isles Lupus Assessment Group [BILAG]
global score > 6); B cell depleted (BCD); responding to rituximab
therapy once B cells had repopulated (rituximab B cell repopu-
lated responding; RBRr; BILAG global score < 6); and not re-
sponding to treatment after B cell repopulation (rituximab B
cell repopulated nonresponding; RBRnr; global score BILAG >
6). A detailed definition of the BILAG index clinical assessment,
clinical information, and treatment regimes of SLE patients
included in the study are provided in Table S1.
We compared iNKT and B cell frequencies in the four patient
groups (Figures 5A–5C). The number of iNKT cells remained
low in PB of patients during the B cell depletion phase (BCD)
independent of clinical response and in patients not responding
to treatment (RBRnr). However, iNKT cell frequency and abso-
lute number were dramatically restored in the responding group
of patients (RBRr) (Figure 5C). Longitudinal analysis of 37 indi-
vidual patients either responding (RBRr) or not responding
(RBRnr) to B cell depletion therapy confirmed that iNKT cell
numbers were mostly recovered in the responding patients
(76.9%) but generally remained low in the RBRnr (87.5%) or in
patients with active SLE treated with nonbiological therapies
(Figures S2A and Figures S2B–S2D). Although there is a general
variability in iNKT cell numbers among healthy donors (Lee et al.,
2002), the frequencies of iNKT cells remained constant in the
same healthy donor over time (Figure S2A).
Similar to iNKT cells from SLE patients prior to rituximab treat-
ment (Figure 3A), iNKT cells from B cell-depleted patients (BCD)Immunity 36, 477–490, March 23, 2012 ª2012 Elsevier Inc. 481
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Figure 3. iNKT Cells from SLE Patients Are Refractory to Further In Vitro Stimulation with aGalCer and IL-2
PBMCs were cultured with aGalCer and IL-2 for 7 days. Supernatants were collected for cytokine analysis and cells were stained with CD3 and iTCR
mAbs.
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B Cells Sustain iNKT Cell Homeostasisand from those not responding to treatment (RBRnr) failed to
expand (Figures 5D and 5E) or to produce a healthy cytokine
profile in response to aGalCer and IL-2 stimulation in 7 day
cultures (Figure 5F). In contrast, the capacity of iNKT cells to
expand and to drive production of IL-2, TNF-a, IFN-g, and
IL-10 was normalized in B cell-repopulated patients responding
to treatment (RBRr) (Figures 5D–5F). Of note, CD1d surface
expression and internalization rate was restored in RBRr but
not in RBRnr patients (Figures 5G–5I). These results suggest
that in this set of patients, newly repopulated B cells may be
reset to a healthy status, as recently suggested (Anolik et al.,
2007), and no longer display the abnormality present in patients
with active SLE.
Immature B Cells from SLE Patients Present Reduced
CD1d Expression
We have shown previously, and confirmed here, that immature
B cells (CD19+CD24hiCD38hi) from healthy donors express
increased amounts of CD1d compared tomature B cells (Figures
6A and 6B; Blair et al., 2010). No significant differences were
observed in the frequency of immature B cells between SLE,
RBRnr, and RBRr patients (Figure 6A); however, analysis of
mature (CD19+CD24intCD38int), memory (CD19+CD24hiCD38),
and immature B cells in healthy donors and in our cohort of
SLE patients revealed that CD1d expression was reduced exclu-
sively in immature B cells from SLE patients (Figure 6B). CD1d
expression remained low on immature B cells from RBRnr
patients but was restored to healthy amounts in RBRr patients
(Figure 6B). A statistically significant positive correlation
between immature B cell and iNKT cell frequencies (but not
mature or memory B cells) was seen only in healthy donors
and in RBRr patients (Figure 6C). The significance of these
results was increased further when those immature B cells ex-
pressing the highest CD1d were correlated with iNKT cell
frequency (Figure 6D).
Immature B Cells from Healthy Donors Are More
Proficient in Promoting iNKT Cell Proliferation and
Cytokine Production than Other B Cell Subsets
Mature or immature B cells from healthy donors were isolated
from PBMCs and cocultured 1:1 with isolated autologous iNKT(A) Representative flow cytometry plots and cumulative data from 21 healthy do
aGalCer and IL-2 stimulation. **p < 0.01; paired t test.
(B) Cytokines from supernatants were measured by CBA. Representative CBA
two-tailed t test.
(C) Experimental design. B cells from healthy donors were negatively isolated, c
7 days with aGalCer and IL-2. Alternatively, negatively isolated B cells from SLE
controls, B cells from healthy donors were cultured with allogeneic B cell-deplete
allogeneic B cell-depleted PBMCs derived from SLE patients.
(D) Bar chart shows mean ± SE fold increase in percentage of iNKT cells at day
(E) IFN-g and TNF-a from supernatants collected in experiment (D) weremeasured
experiments each with five healthy donors and five SLE patients, mean ± SE. *p
(F) Monocytes from healthy donors or SLE patients were isolated with anti-CD14 b
differentiate into DCs. At day 4, immature DCs were stimulated with 100 ng/ml lip
cultured for 7 days with autologous CD14+monocyte-depleted PBMCs from healt
is shown in Figure S5D. Representative flow cytometry plots showing frequency o
with autologous monocyte-depleted PBMCs from healthy donors and SLE patien
five SLE patients. *p < 0.05; paired t test.
(G) Cytokines from supernatants collected in experiment (F) weremeasured byCB
of two separate experiments.cells for 3 days in the presence of aGalCer and IL-2. iNKT cell
proliferation and IFN-g production was consistently higher in
immature B cell cocultures, compared to mature B cells (Figures
7A and 7B). The experiments described above are technically
difficult to perform because of the scarcity of both cell popula-
tions in PB. To dissect further the role of CD1dhi immature B cells
in iNKT cell homeostasis, we depleted mature or CD1dhi imma-
ture B cells from PBMCs prior to stimulation with aGalCer and
IL-2. Depletion of immature B cells reduced iNKT cell expansion
and cytokine production compared to whole PBMCs and deple-
tion of mature B cells (Figures 7C and 7D). These results indicate
a preferential role for immature B cells compared to mature B
cells in iNKT cell homeostasis in healthy donors.
We propose that among different B cell subsets, immature B
cells with high expression of CD1d are pivotal for iNKT cell
homeostasis in healthy donors. Furthermore, defects in CD1d
expression in immature B cells, possibly induced by factors
contributing to SLE pathogenesis, may play a role in iNKT
dysfunction in these patients.
DISCUSSION
Several reports have demonstrated that B cells interact either
directly or indirectly with iNKT cells (Bialecki et al., 2009; Tonti
et al., 2009) and that B cell presentation of aGalCer to iNKT cells
generates a specific activation signal that drives memory B cell
or plasma cell differentiation (Barral et al., 2008; Galli et al.,
2007; Lang et al., 2008; Leadbetter et al., 2008). However, the
effect that lipid-antigen presentation by B cells has on iNKT
cell function remains largely uninvestigated.
We report a previously unappreciated role for B cells in the
maintenance of iNKT cell homeostasis. B cells from SLE patients
showed altered CD1d recycling and impaired iNKT cell activa-
tion a phenomenon that could be observed in B cells from
healthy donors after simultaneous stimulation with IFN-a and
anti-Ig. IFN-a is implicated in SLE etiology and pathogenesis
(Pascual et al., 2003). SLE-associated autoantibodies can drive
IFN-a release and its increased production can inhibit immune
regulation (Pace et al., 2010). Excessive signaling via the BCR
and elevated circulating IFN-a may account for the defective
CD1d-mediated lipid presentation by B cells leading to reducednors and 22 SLE patients showing frequencies of iNKT cells before and after
plot and bar charts with cumulative data are shown. Mean ± SE. *p < 0.05;
ocultured with B cell-depleted PBMCs from SLE patients, and stimulated for
patients were cultured with B cell-depleted PBMCs from healthy donors. As
d PBMCs from healthy donors or B cells from SLE patients were cultured with
7 compared to day 0. *p < 0.05, **p < 0.01; one-way ANOVA.
byCBA. Representative CBA plot and cumulative data from three independent
< 0.05, **p < 0.01; one-way ANOVA.
eads, stimulated with 1,000 IU/ml GM-CSF and 500 IU/ml IL-4, and allowed to
opolysacharide (LPS) and aGalCer for 24 hr. aGalCer-pulsed mature DCs were
hy donors or SLE patients with 200 IU/ml IL-2. Purity of monocyte-derived DCs
f iNKT cells at day 0 and 7 from cultures with monocyte-derived DCs together
ts; bar chart shows cumulative data, mean ± SE from five healthy donors and
A. Results from five healthy donors and five SLE patients shown, representative
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Figure 4. Defects in CD1d Surface Expression and Intracellular Recycling on B Cells from SLE Patients
PBMCs from healthy donors and SLE patients with active disease were surface stained with CD19, CD14, and CD1d mAbs.
(A) Representative histograms showing surface expression of CD1d on CD19+ B cells or on CD14+ cells from SLE patients compared to healthy
donors. Scatter plots showing mean fluorescent intensity (MFI) of CD1d on B cells from 42 healthy donors and 33 SLE patients. *p < 0.05, **p < 0.01; one-way
ANOVA.
(B–D) B cells were negatively isolated from eight SLE patients and six healthy donors and stimulated with PMA for 1 hr to force CD1d to the surface. CD1d-bearing B
cellswere thenfixedandculturedwithautologousBcell-depletedPBMCswithaGalCerand IL-2±blockingCD1dmAb for iNKTcell expansion for anadditional 7days.
(B) Representative histograms showing increased CD1d surface expression after PMA treatment of B cells from SLE patients.
(C) Bar chart showsmean ± SE fold increase in percentage of iNKT cells at day 7 in CD1d ‘‘forced’’ cells compared to CD1d unforced cells ± blocking CD1dmAb.
(D) Cytokines in supernatants collected from experiment (C) were measured by CBA. Representative CBA plot and cumulative results from two independent
experiments each with five healthy donors and five SLE patients, mean ± SE.
(E and F) B cells were negatively isolated from three healthy donors and three SLE patients and stimulated with PMA for 1 hr. B cells were then stained with CD1d
mAb on ice. B cells were incubated at 37C for several time points to allow CD1d endocytosis.
(E) Internalization was determined by flow cytometry after quenching of surface CD1d expression and expressed as mean ± SE percentage CD1d internalization.
One of three experiments is shown.
(F) Representative confocal microscopy analysis showing CD1d localization on B cells from five healthy donors and five SLE patients at 0 and 5 min after CD1d
endocytosis was allowed to proceed. Cells stained for CD1d (green) and DAPI (blue). Scale bars represent 1 mm. Arrows indicate CD1d internalization.
(G–J) B cells from healthy donors or SLE patients were stained with unconjugated CD1d mAb, incubated at 37C for 20 min to allow recycling of intracellular
CD1d, followed by detection of newly formed surface CD1d with CD1d-PE mAb.
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B Cells Sustain iNKT Cell HomeostasisiNKT cell frequency. Our results suggest a sustained B cell
dysfunction as indicated by the fact that patients with reduced
disease activity undergoing nonbiological treatment do not
recover CD1d expression on B cells (data not shown). Although
CD1d expression on B cells is required for iNKT cell proliferation
and activation, further investigations are needed to understand
whether factors other than CD1d (which could have been
induced in our experimental system) are important for the main-
tenance of iNKT cells.
A remaining conundrum is why in vivo APCs expressing
a normal amount of CD1d do not compensate for the reduction
of CD1d on B cells, especially because DCs are shown to be
the most effective iNKT cell stimulators (Bezbradica et al.,
2005; Im et al., 2009). It is possible that in addition to CD1d, B
cells provide other signals essential for iNKT cell expansion,
absent on DCs and monocytes. Alternatively, a determining
factor may be the physiological location of the interaction.
More experiments are needed to fully clarify the mechanisms
underlying reduced surface expression of CD1d exclusively on
B cells from SLE patients including its intracellular location
during recycling and its impact on iNKT cell homeostasis.
It has been suggested that the reduction of iNKT cells in auto-
immunity is genetically linked, a finding supported by the
concomitant iNKT cell reduction identified in first-degree rela-
tives of SLE patients (Wither et al., 2008). Of note, many of these
relatives suffered from autoimmune diseases, which could
account for their reduced iNKT cell frequencies. The longitudinal
analysis of rituximab-treated patients shows that reduced iNKT
cell frequency was a reversible phenomenon, restored in re-
sponding patients upon reconstitution of immature B cells with
normal CD1d expression. Furthermore, iNKT cells from SLE
patients were able to respond normally when primed by autolo-
gous mDCs, suggesting an acquired rather than intrinsic defect.
It is possible that reduced iNKT cell number in PB could be the
result of iNKT cells migrating to sites of inflammation. Inflamma-
tion per se did not affect iNKT cell number in PB, as shown by the
fact that disease activity did not reflect a variation in iNKT cell
frequency. Restoration of iNKT cell numbers was a primary
feature of patients responding to rituximab treatment after B
cell repopulation, as shown by the fact that SLE patients with
inactive disease treated with nonbiological therapies or during
the B cell-depletion phase (no detectable B cells in PB) had a
lower number of iNKT cells compared to healthy donors. Of
interest, the peripheral numerical deficiency seems to be(G) Cumulative data showingMFI of CD1d recycling to the surface of B cells from h
in B cells incubated at 37C compared to B cells left on ice are shown, mean perc
were obtained when intracellular protein trafficking was blocked with Brefeldin A
(H) Protein immunoblot analysis of total cellular CD1d protein in B cells from either
actin control. Mean ± SE of three healthy donors and three SLE patients.
(I) PBMCs were cultured in the presence or absence of proteosome inhibitor MG1
showing fold change in CD1d expression on B cells cultured with MG123 compa
and five SLE patients.
(J) B cells from healthy donors were negatively isolated and stained on ice for C
IFN-a and/or anti-Ig F(ab’)2 to allow CD1d endocytosis. Internalization was determ
donors.
(K and L) iNKT cells were cultured 1:1 with autologous CD19+ B cells for 3 days wi
flow cytometry.
(K) Representative flow cytometry plots and cumulative data (on the right) showi
(L) IFN-g in supernatants collected from experiment (K) measured by ELISA. Barconfined to iNKT cells as other immune-regulatory cells, such
as regulatory B cells (Breg) are increased in the periphery of
patients with active SLE (Blair et al., 2010).
iNKT cells from SLE patients failed to proliferate and release
IFN-g but produced equivalent amounts of IL-4. Previous work
in mice has shown that a single administration of aGalCer
induces iNKT cell anergy, defined by their inability to proliferate
and produce IFN-g while producing IL-4. Anergy was reversed
after addition of exogenous IL-2 (Parekh et al., 2005). Expression
of programmed death-1 (PD-1) was increased in iNKT cells
from SLE patients (data not shown), characteristic of an anergic
or exhausted phenotype in iNKT and conventional T cells (Keir
et al., 2008; Parekh et al., 2009). In vivo, multiple factors
contribute to the profound hyporesponsive phenotype of iNKT
cells from SLE patients, including exposure to elevated quanti-
ties of immunosuppressive cytokines such as IL-10 or transform-
ing growth factor-b (TGF-b), abundantly present in these patients
(Isenberg and Rahman, 2006; and E.C.J., data not shown).
The biological significance of iNKT cell deficiency in autoim-
mune patients remains controversial. This is primarily a result
of the lack of uniformity in themethods used to identify iNKT cells
and to the limited functional analysis that has been performed
(Berzins et al., 2011). Most information supporting an immune-
regulatory role for iNKT cells in autoimmunity comes from
studies performed in mice (Cerundolo et al., 2009). Experimental
strategies focused on increasing the number or stimulation of
iNKT cells in a variety of experimental models show an enhanced
degree of protection against the development of autoimmunity
(Mars et al., 2004). Protective mechanisms exerted by iNKT cells
include inhibition of autoreactive B cells, induction of tolerogenic
DCs, and the indirect induction of Treg cells (Ly et al., 2006; Nau-
mov et al., 2001; Wermeling et al., 2010; Yang et al., 2011). The
finding showing that iNKT cell numbers were restored in patients
responding to rituximab only after the repopulation of B cells with
normalized CD1d expression suggests that iNKT cells may
contribute directly or indirectly to the amelioration of SLE.
The benefit of rituximab therapy in SLE patients has been
attributed to different mechanisms of action including depletion
of effector B cells from target organs followed by a reduction
of autoantibody production, restoration of normal Th1 and Th2
cytokine balance, and an increase of Treg cells, although this
remains controversial (Edwards and Cambridge, 2006; Sfikakis
et al., 2007). We provide an additional mechanism showing
that B cell-depletion therapy may rebalance altered immuneealthy donors (n = 6) compared to SLE patients (n = 6). Differences in CD1dMFI
entage ± SE from two experiments. **p < 0.01; two-tailed t test; similar results
, instead of leaving cells on ice (data not shown).
healthy donors or SLE patients. Cumulative data show quantification relative to
23 for 4 hr. CD1d expression was assessed by flow cytometry. Cumulative data
red to B cells cultured with DMSO as control. Mean ± SE of five healthy donors
D1d. B cells were incubated at 37C for 15 min in the presence or absence of
ined as in (E). Bar charts showmean ± SE. CD1d internalization in five healthy
th aGalCer and IL-2 ± IFN-a and anti-Ig. Both iNKT and B cells were purified by
ng frequency of Ki67+ iNKT cells.
charts with cumulative data from three healthy donors, mean ± SE.
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Figure 5. iNKT Cell Number Is Recovered in SLE Patients Responding to Rituximab after B Cell Repopulation
Ex vivo PBMCs from SLE patients before, during, and after rituximab treatment stained for expression of CD19, CD3, and iTCR.
(A) Representative flow cytometry plots showing frequency of iNKT and B cells from SLE patients, B cell-depleted SLE patients (BCD), repopulated non-
responding SLE patients (RBRnr), and repopulated responding patients (RBRr).
(B and C) Scatter plots show mean percentage of B cells (B) and percentage and absolute number of iNKT cells (C) in PB of 254 SLE, 92 BCD, 32 RBRnr, and
113 RBRr patients. *p < 0.05, **p < 0.01; one-way ANOVA.
(D and E) PBMCs isolated from SLE patients before, during, and after rituximab treatment were cultured with aGalCer and IL-2 for 7 days. Supernatants were
collected and cells were stained with CD3 and iTCRmAbs. Representative flow cytometry plots at day 7 (D) and bar charts showing the cumulative data of iNKT
cells (E) before and after the 7 day culture from 10 SLE, 10 BCD, 13 RBRnr, and 13 RBRr patients. **p < 0.01; paired t test.
(F) Cytokines from supernatants collected in experiment (D) were measured by CBA. Bar charts of cumulative results from three independent experiments with
10 SLE, 10 BCD, 13 RBRnr, and 13 RBRr patients, mean ± SE. *p < 0.05, **p < 0.01; one-way ANOVA.
(G) Ex vivo PBMCs from SLE patients before, during, and after rituximab treatment stained for expression of CD19 and CD1d. Scatter plots showing CD1dMFI on
B cells in PB of 42 healthy donors, 33 SLE patients, 21 RBRnr, and 66 RBRr patients. *p < 0.05; one-way ANOVA.
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Figure 6. CD1dhi Immature B Cells Positively Correlate with the Frequency of iNKT Cells in Healthy Donors and Patients Responding
to Rituximab
PBMCs from either healthy donors or SLE patients were stained for expression of CD19, CD24, CD38, and CD1d to identify B cell subsets.
(A) Representative flow cytometry plot showing CD19+CD24hiCD38hi (immature), CD19+CD24+CD38 (memory), and CD19+CD24intCD38int (mature) B cells
(Blair et al., 2010). Representative histograms displaying CD1d expression on mature, memory, and immature B cells from healthy donors, SLE patients, RBRnr,
and RBRr patients.
(B) Scatter plots showing frequency of immature B cells in 25 healthy donors, 134 SLE patients, 21 RBRnr, and 66 RBRr patients.
(C) Volcano plot showing individual Spearman’s correlations for frequency of iNKT cells compared to frequency of mature, memory, and immature B cells from
healthy donors, SLE patients, RBRnr, and RBRr patients versus the statistical significance.
(D) Representative dot plot showing the gating strategy for CD1dhi expression on immature B cells. Correlation plots show the relationship between frequency of
CD1dhi B cells and iNKT cells in RBRr patients. Each dot, representative of a patient, is colored based on its disease activity calculated with the BILAG scoring
system. Spearman’s correlation.
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B Cells Sustain iNKT Cell Homeostasisresponses in SLE patients by restoring defective iNKT cells to
healthy function in responding patients. Immature B cells from
healthy donors, expressing the highest amount of CD1d among
different B cell subsets, possess a regulatory function and
suppress CD4+ T cell activation via the provision of IL-10 (Blair
et al., 2010). In healthy donors, this population promotes higher
iNKT cell proliferation and IFN-g production compared tomature
B cells. We have shown that CD1d expression was reduced
exclusively on immature B cells from SLE patients and was
recovered in responding patients. Statistical analysis of our
data revealed a significant positive correlation between the(H) Bar chart showing CD1d internalization on B cells from three healthy donors, th
experiments is shown. Mean percentage ± SE. ***p < 0.001; one-way ANOVA.
(I) Confocal microscopy analysis depicting CD1d localization on B cells from one R
were stained for CD1d (green) and DAPI (blue). Scale bars represent 1 mm. ArrowiNKT cell percentages, immature B cells, and a better clinical
outcome. Expansion of immature B cells has been shown previ-
ously to correlate with a long-term favorable response in SLE
and in RA patients treated with rituximab (Anolik et al., 2007;
Leandro et al., 2006). It is tempting to envisage a scenario where
Breg cells, as opposed to other CD1d-expressing B cells, impart
the differentiation of iNKT cells with immune-regulatory function
via presentation of endogenous lipid or protein antigen.
In summary, we report that B cell-iNKT cell interaction is
important for the maintenance of iNKT cell homeostasis and
that it requires the presence of functionally normal B cells.ree SLE patients, three RBRnr, and three RBRr patients after 5min. One of three
BRnr and one RBRr patient before (0) and 5 min after CD1d endocytosis. Cells
s indicate areas of CD1d internalization.
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Figure 7. iNKT Cell Proliferation and Cytokine
Production Is Preferentially Induced by Immature
Compared to Mature B Cells
Flow cytometry-sorted iNKT cells from healthy donors
were cultured 1:1 with autologous flow cytometry-sorted
immature or mature B cells for 3 days with or without
aGalCer and IL-2.
(A) Representative flow cytometry plots of three healthy
donors showing frequencies of Ki67+ iNKT cells.
(B) IFN-g in supernatants collected from experiment (A)
measured by ELISA. A representative experiment of two is
shown.
PBMCs from healthy donorswere stained for CD19, CD24,
and CD38 and gated as shown in Figure 6A. Immature or
mature B cells were depleted, by flow cytometry sorting,
from PBMCs and the remaining PBMCs were collected,
cultured for 7 days with aGalCer and IL-2, and surface
stained with CD3 and iTCR mAbs.
(C) Representative flow cytometry plots depicting iNKT
cells from undepleted, mature, or immature B cell-
depleted PBMCs of three healthy before and after 7-day
culture.
(D) Cytokines in supernatants collected from experiment
(C) measured by ELISA. Bar charts show cumulative data
from six healthy donors, mean ± SE. *p < 0.05; two-tailed t
test.
Immunity
B Cells Sustain iNKT Cell HomeostasisAdditionally, we propose that B cell-iNKT cell cross-talk is dis-
rupted in SLE patients and that rituximab treatment may work,
in part, by resetting the outcome of B cell-iNKT cell interactions.488 Immunity 36, 477–490, March 23, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Patients and Controls
Table S1 provides detailed information of patient charac-
teristics and treatment. Ethical approval was obtained
from University College Hospital ethics committee.
PBMC, B Cell, and iNKT Cell Isolation
PBMCs were isolated by Ficoll-Paque Plus (GE Health-
care) gradient centrifugation, resuspended to 107 cells/ml
in FCS (Biosera) and 5% DMSO (Sigma-Aldrich), and
frozen until subsequent use. Unmanipulated B cells were
negatively isolated and monocytes or B cells were
depleted from PBMCs by positive selection with magnetic
beads (Miltenyi, Biotec). B cell subsets or iNKT cells were
isolated with the FACSAria (Beckton, Dickinson) based on
expression of CD19, CD24, CD38 or CD3, and iTCR,
respectively. Alternatively, iNKT cells were isolated with
anti-iTCR magnetic beads (Miltenyi, Biotec). Figures
S5A–S5C shows purity of B cells and iNKT cells. Absolute
numbers from healthy donors were calculated by multi-
plying 103 the total number of cells isolated from 100 ml
of blood by the fraction of PBMCs contained within each
subset determined by flow cytometry.
Cell Cultures
For iNKT cell expansion, PBMCs were cultured in RPMI
1640, L-glutamine and NaHCO3 (Sigma-Aldrich), 10%
human serum type AB (Lonza), 100 U/mg/ml penicillin/
streptomycin (Sigma-Aldrich), 200 IU/ml recombinant
human (rh)IL-2 (R&D Systems), and 100 ng/ml aGalCer
(Alexis Biochemicals). For iNKT and B cell cocultures,
negatively isolated B cells were pulsed with 100 ng/ml
aGalCer for 1 hr at 37C. B and iNKT cells were cocultured
with isotype control or 10 mg/ml purified CD1d blockingmAb (51.1). Alternatively, PBMCs from healthy donors or SLE patients were
cultured in the presence or absence of a protease inhibitor (MG123; Sigma-
Aldrich) for 4 hr to determine the rate of CD1d proteosomal degradation.
Immunity
B Cells Sustain iNKT Cell HomeostasisThe efficacy of MG123 was confirmed by assessing the accumulation of
ubiquitinated protein species by protein immunoblotting (data not shown).
Experimental procedures related to CD1d quantitative immunoblotting,
CD1d internalization, and recycling are described in Supplemental Experi-
mental Procedures.
Forcing CD1d to the B Cell Surface
Negatively isolated B cells from SLE patients were stimulated with 10 ng/ml
PMA (Sigma-Aldrich) for 1 hr to force CD1d to the surface, fixed with 2%
PFA (Sigma-Aldrich), and cultured with untouched, autologous B cell-depleted
PBMCs for 7 days in the presence of 200 IU/ml rhIL-2 and 100 ng/ml aGalCer
for iNKT cell expansion.
Thymidine Incorporation
B and iNKT cell cocultures were incubated with 0.5 mCi (0.0185 MBq)/well
[3H]thymidine (TdR; Hartmann Analytik) for the last 16 hr of culture. Cells
were harvested (Tomtec) prior to quantification of [3H]TdR incorporation on
a scintillation counter (PerkinElmer).
Flow Cytometry
For iNKT cell staining, CD3-FITC, iTCR-PE, CD69-PECy7, and CD25-APC
mAbs were used. For staining CD1d on monocytes and B cells, CD14-FITC,
CD19-PECy7, CD38-PECy5, CD24-FITC, and CD1d-PE mAbs were used.
Purity of monocyte-derived DCs was determined with DC-SIGN-APC mAb.
Ki67 expression was detected according to manufacturer’s instructions (BD,
Bioscience). For analysis of human intracellular cytokine production, PBMCs
were stimulated for 4 hr with 50 ng/ml PMA, 250 ng/ml ionomycin (Sigma-
Aldrich), and Golgi-Plug (BD, Biosciences) in complete medium. For intracel-
lular staining, cells were stained with combinations of CD3-FITC, iNKT-PE,
IFN-g-PECy7, IL-10-APC, or TNF-a-APC mAbs or appropriate isotype
controls. Data were acquired on an LSRII (Beckton, Dickinson) and analyzed
with FlowJo (TreeStar). Supernatants were collected from PBMC cultures for
iNKT cell expansion. IL-2, IL-4, TNF-a, IL-6, IL-10, and IFN-g were measured
in supernatants by CBA (BD Biosciences) as described by the manufacturer’s
instructions and analyzed on a FACSArray (Beckton, Dickinson). Alternatively,
TNF-a, IL-10, and IFN-g were measured in supernatants by ELISA (R&D
Systems).
Statistical Analysis
Values are expressed as absolute mean ± SE. Data were tested for normal
distribution by the Kolmogorov-Smirnov test and analyzed for significance in
GraphPad Prism (La Jolla, CA) by two-tailed t test, paired t test, or one-way
ANOVA as specified. Correlation coefficients and their significance were
calculated by two-tailed Spearman’s rank correlation.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
doi:10.1016/j.immuni.2012.02.008.
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